$LUCD
Lucid Diagnostics Inc. Stock $lucd

$lucd Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017413 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$159.0K	$446.0K	$189.0K
YoY Change		135.98%
Cost Of Revenue	$1.549M	$1.338M	$369.0K
YoY Change		262.6%
Gross Profit	-$1.390M	-$892.0K	-$180.0K
YoY Change		395.56%
Gross Profit Margin	-874.21%	-200.0%	-95.24%
Selling, General & Admin	$7.862M	$10.64M	$9.209M
YoY Change	-29.7%	15.52%
% of Gross Profit
Research & Development	$1.827M	$2.282M	$2.881M
YoY Change	-46.89%	-20.79%
% of Gross Profit
Depreciation & Amortization	$633.0K	$612.0K	$24.00K
YoY Change	-10.09%	2450.0%
% of Gross Profit
Operating Expenses	$11.74M	$14.76M	$12.09M
YoY Change	-19.7%	22.11%
Operating Profit	-$11.58M	-$14.32M	-$12.27M
YoY Change	-20.79%	16.68%
Interest Expense	$223.0K	$33.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$203.0K	-$1.930M	$1.000K
YoY Change		-193100.0%
Pretax Income	-$11.38M	-$16.25M	-$12.27M
YoY Change	-22.18%	32.41%
Income Tax
% Of Pretax Income
Net Earnings	-$11.38M	-$16.25M	-$12.27M
YoY Change	-22.18%	32.41%
Net Earnings / Revenue	-7157.86%	-3642.83%	-6492.06%
Basic Earnings Per Share	-$0.27	-$0.40	-$0.35
Diluted Earnings Per Share	-$0.27	-$0.40	-$344.6K
COMMON SHARES
Basic Shares Outstanding	43.73M shares	43.39M shares	35.12M shares
Diluted Shares Outstanding	41.83M shares	40.97M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.57M	$39.52M	$47.92M
YoY Change	-0.33%	-17.52%
Cash & Equivalents	$32.57M	$39.52M	$47.92M
Short-Term Investments
Other Short-Term Assets	$3.144M	$2.172M	$4.324M
YoY Change	-1.63%	-49.77%
Inventory
Prepaid Expenses
Receivables	$35.00K	$27.00K	$89.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$35.75M	$41.72M	$52.33M
YoY Change	-0.35%	-20.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.389M	$1.502M	$3.319M
YoY Change	9.72%	-54.75%
Goodwill
YoY Change
Intangibles	$2.435M	$2.940M
YoY Change	-45.35%
Long-Term Investments
YoY Change
Other Assets	$1.078M	$1.078M	$695.0K
YoY Change	-37.47%	55.11%
Total Long-Term Assets	$6.737M	$7.404M	$9.728M
YoY Change	-29.28%	-23.89%
TOTAL ASSETS
Total Short-Term Assets	$35.75M	$41.72M	$52.33M
Total Long-Term Assets	$6.737M	$7.404M	$9.728M
Total Assets	$42.49M	$49.13M	$62.06M
YoY Change	-6.42%	-20.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$637.0K	$625.0K	$4.462M
YoY Change	-73.52%	-85.99%
Accrued Expenses	$3.739M	$3.241M	$2.995M
YoY Change	83.02%	8.21%
Deferred Revenue
YoY Change
Short-Term Debt	$22.31M	$19.53M	$1.770M
YoY Change	818.36%	1003.22%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.68M	$23.39M	$14.11M
YoY Change	238.7%	65.74%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$732.0K	$826.0K	$1.455M
YoY Change	-42.9%	-43.23%
Total Long-Term Liabilities	$732.0K	$826.0K	$1.455M
YoY Change	-42.9%	-43.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.68M	$23.39M	$14.11M
Total Long-Term Liabilities	$732.0K	$826.0K	$1.455M
Total Liabilities	$27.42M	$24.22M	$15.57M
YoY Change	199.29%	55.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.7M	-$114.3M
YoY Change	82.71%
Common Stock	$42.00K	$42.00K
YoY Change	16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.07M	$24.91M	$46.49M
YoY Change
Total Liabilities & Shareholders Equity	$42.49M	$49.13M	$62.06M
YoY Change	-6.42%	-20.84%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$11.38M	-$16.25M	-$12.27M
YoY Change	-22.18%	32.41%
Depreciation, Depletion And Amortization	$633.0K	$612.0K	$24.00K
YoY Change	-10.09%	2450.0%
Cash From Operating Activities	-$7.012M	-$7.045M	-$5.776M
YoY Change	-47.3%	21.97%
INVESTING ACTIVITIES
Capital Expenditures	$15.00K	$17.00K	-$148.0K
YoY Change	-106.36%	-111.49%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$15.00K	-$17.00K	-$148.0K
YoY Change	-99.38%	-88.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	75.00K	$24.11M	187.0K
YoY Change	-85.03%	12793.05%
NET CHANGE
Cash From Operating Activities	-7.012M	-$7.045M	-5.776M
Cash From Investing Activities	-15.00K	-$17.00K	-148.0K
Cash From Financing Activities	75.00K	$24.11M	187.0K
Net Change In Cash	-6.952M	$17.05M	-5.737M
YoY Change	-54.38%	-397.16%
FREE CASH FLOW
Cash From Operating Activities	-$7.012M	-$7.045M	-$5.776M
Capital Expenditures	$15.00K	$17.00K	-$148.0K
Free Cash Flow	-$7.027M	-$7.062M	-$5.628M
YoY Change	-46.23%	25.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001799011
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022Q1	us-gaap	Interest Expense InterestExpense		usd
CY2022Q1	LUCD	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote		usd
CY2022Q1	LUCD	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q1	LUCD	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote		usd
CY2022Q1	LUCD	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote		usd
CY2022Q1	LUCD	Issue Common Stock Settle Termination Payment IssueCommonStockSettleTerminationPayment		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022Q1	LUCD	Proceeds From Issuance Of Common Stock One ProceedsFromIssuanceOfCommonStockOne		usd
CY2023Q1	us-gaap	Operating Cost And Expense Related And Nonrelated Party Status Extensible Enumeration OperatingCostAndExpenseRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q1	us-gaap	Operating Cost And Expense Related And Nonrelated Party Status Extensible Enumeration OperatingCostAndExpenseRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	us-gaap	Operating Cost And Expense Related And Nonrelated Party Status Extensible Enumeration OperatingCostAndExpenseRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q1	us-gaap	Operating Cost And Expense Related And Nonrelated Party Status Extensible Enumeration OperatingCostAndExpenseRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40901
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	LUCID DIAGNOSTICS INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5488042
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	360 Madison Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	25th Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
CY2023Q1	dei	City Area Code CityAreaCode	(212)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	949-4319
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	LUCD
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43725703	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39522000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22474000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2172000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1865000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	41721000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	24356000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1502000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1592000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1884000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2008000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2940000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3445000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1078000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1108000	usd
CY2023Q1	us-gaap	Assets Assets	49125000	usd
CY2022Q4	us-gaap	Assets Assets	32509000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	625000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1056000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2190000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1447000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1051000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	962000	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	11900000	usd
CY2023Q1	LUCD	Msa Fee Operating Expenses And Interest Expense MSAFeeOperatingExpensesAndInterestExpense	7627000	usd
CY2022Q4	LUCD	Msa Fee Operating Expenses And Interest Expense MSAFeeOperatingExpensesAndInterestExpense	4960000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	23393000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8425000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	826000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1037000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	24219000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9462000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	13625000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41753603	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41753603	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40518792	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40518792	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	42000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	41000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125561000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121081000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114322000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98075000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	24906000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23047000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49125000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32509000	usd
CY2023Q1	us-gaap	Revenues Revenues	446000	usd
CY2022Q1	us-gaap	Revenues Revenues	189000	usd
CY2023Q1	LUCD	Operating Cost Of Revenue OperatingCostOfRevenue	1338000	usd
CY2022Q1	LUCD	Operating Cost Of Revenue OperatingCostOfRevenue	369000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4127000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3318000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6511000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5892000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2282000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2881000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14763000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	12460000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14317000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12271000	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	78000	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	1000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	33000	usd
CY2023Q1	LUCD	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	789000	usd
CY2023Q1	LUCD	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	1186000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1930000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16247000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12270000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16247000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-12270000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40970504	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35123039	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23047000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2817000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	391000	usd
CY2023Q1	LUCD	Stock Issued During Period Value Asset Acquisitions Termination Payment StockIssuedDuringPeriodValueAssetAcquisitionsTerminationPayment	713000	usd
CY2023Q1	LUCD	Issuance At The Market Facility Net Of Deferred Financing Charges IssuanceAtTheMarketFacilityNetOfDeferredFinancingCharges	284000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	276000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13625000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16247000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	24906000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	54739000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	54739000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	187000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3537000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	298000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-12270000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	46491000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	46491000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16247000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-12270000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	612000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2817000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3537000	usd
CY2023Q1	LUCD	Share Based Compensation Of Parent ShareBasedCompensationOfParent	391000	usd
CY2022Q1	LUCD	Share Based Compensation Of Parent ShareBasedCompensationOfParent	298000	usd
CY2023Q1	LUCD	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	789000	usd
CY2023Q1	LUCD	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	1186000	usd
CY2023Q1	LUCD	Issue Common Stock Settle Termination Payment IssueCommonStockSettleTerminationPayment	713000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-111000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	275000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-168000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-431000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1958000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	743000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	285000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2667000	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	113000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7045000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5776000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	148000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-148000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	13625000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	9925000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	284000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	187000	usd
CY2023Q1	LUCD	Proceeds From Issuance Of Common Stock One ProceedsFromIssuanceOfCommonStockOne	276000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24110000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	187000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17048000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5737000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22474000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	53656000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39522000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47919000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zrtCIRLaPLs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_znRv478YqpFh">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards and intangible assets. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	LUCD	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	35000	usd
CY2022Q4	LUCD	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	52000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2172000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1865000	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zbzxynrikFV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zt4AkNPE6zHl">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.</span></p>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	446000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	189000	usd
CY2023Q1	LUCD	Cost Of Revenue Related To Laboratory Operations And Distributions CostOfRevenueRelatedToLaboratoryOperationsAndDistributions	1338000	usd
CY2023Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	646000	usd
CY2022Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	338000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	4960000	usd
CY2023Q1	LUCD	Msa Fees MsaFees	2250000	usd
CY2023Q1	LUCD	On Behalf Of Obo Activities OnBehalfOfOboActivities	219000	usd
CY2023Q1	LUCD	Erc Payroll Benefits ErcPayrollBenefits	484000	usd
CY2023Q1	LUCD	Cash Payments CashPayments	-286000	usd
CY2023Q1	us-gaap	Other Receivables OtherReceivables	7627000	usd
CY2023Q1	LUCD	Termination Expense TerminationExpense	713000	usd
CY2023Q1	LUCD	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	308000	usd
CY2022Q4	LUCD	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	371000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	76000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	52000	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	1726000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	1331000	usd
CY2023Q1	LUCD	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	27000	usd
CY2022Q4	LUCD	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	59000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	870000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1071000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	65000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2006000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	129000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1877000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	285000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	224000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	125000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2404000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M7D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M19D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1884000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2008000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1877000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1999000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1051000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	962000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	826000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1037000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5305000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5305000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-2365000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1860000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2940000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3445000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1516000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	688000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	421000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	315000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2940000	usd
CY2023Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	11900000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	11100000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	11111000	usd
CY2023Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	11900000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-789000	usd
CY2023Q1	LUCD	Covenant Description CovenantDescription	(i) a minimum of $5.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, as of the last day of any fiscal quarter commencing with September 30, 2023, to not exceed 30%; and (iii) the Company’s market capitalization to at no time be less than $30 million
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3208000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3835000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.86	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017	pure
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41753603	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41753603	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40518792	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40518792	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16247000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-12270000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40970504	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35123039	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20620408	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5125167	shares

Files In Submission

Name	View Source	Status
lucd-20230331_def.xml	Edgar Link	unprocessable
lucd-20230331_cal.xml	Edgar Link	unprocessable
0001493152-23-017413-index-headers.html	Edgar Link	pending
0001493152-23-017413-index.html	Edgar Link	pending
0001493152-23-017413.txt	Edgar Link	pending
0001493152-23-017413-xbrl.zip	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-7_001.jpg	Edgar Link	pending
ex10-7_002.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
lucd-20230331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
lucd-20230331_lab.xml	Edgar Link	unprocessable
lucd-20230331_pre.xml	Edgar Link	unprocessable
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUCD
Lucid Diagnostics Inc. Stock $lucd

2023 Q2 Form 10-Q Financial Statement

#000149315223017413 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUCD Lucid Diagnostics Inc. Stock $lucd

2023 Q2 Form 10-Q Financial Statement

#000149315223017413 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUCD
Lucid Diagnostics Inc. Stock $lucd